Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

P. Neven, B. Van Calster, I. Van Den Bempt, S. Van Huffel, V. Van Belle, Wouter R. Hendrickx, Julie Decock, H. Wildiers, R. Paridaens, F. Amant, K. Leunen, P. Berteloot, D. Timmerman, E. Van Limbergen, C. Weltens, W. Van Den Bogaert, A. Smeets, I. Vergote, M. R. Christiaens, M. Drijkoningen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely HER-2 + and HER-2+ tumours are less likely ER+. Methods: We studied the age-related immunohistochemical (IHC) expression of ER, progesterone receptor (PR) and HER-2 in 2,227 tumours using age as a continuous variable. Steroid receptors were considered positive for any nuclear staining of invasive cancer cells and for HER-2, either for strong expression by IHC (score 3+) or gene amplification by fluorescence in situ hybridisation (FISH). Based on nonparametric regression, the age-related association between steroid receptors and HER-2 was presented as likelihood curves. Results: The association between ER or PR and HER-2 is age-related. The age-related expression of ER and PR is HER-2 dependent. In HER-2- cases, the odds ratio (OR) for being ER+ was 2.594 (95% CI = 1.874-3.591) up to age 50 and age-independent thereafter; for PR-expression the OR was 2.687 (95% CI = 1.780-4.057) up to age 45 and 0.847 (95% CI = 0.761-0.942) thereafter. In HER-2+ cases, the OR was 0.806 (95% CI = 0.656-0.991) to be ER + and 0.722 (95% CI = 0.589-0.886) to be PR+. The age-related OR for breast cancers to be HER-2+ is steroid receptor dependent. Taking together, ER+PR+HER-2+ breast cancers appear on average 5.4 years earlier than breast cancers of any other ER/PR/HER-2 phenotype (95% CI = 3.3-7.5; P < 0.0001). Conclusion: There is a qualitative interaction between age and expression of steroid and HER-2 receptors. Our findings suggest a strong age-related selective growth advantage for breast tumour cells belonging to the ER+PR+HER-2 + subgroup.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalBreast Cancer Research and Treatment
Volume110
Issue number1
DOIs
Publication statusPublished - 1 Jul 2008
Externally publishedYes

Fingerprint

Steroids
Breast Neoplasms
Progesterone Receptors
Steroid Receptors
Odds Ratio
human ERBB2 protein
Neoplasms
Gene Amplification
Fluorescence In Situ Hybridization
Estrogen Receptors
Staining and Labeling
Phenotype

Keywords

  • Breast cancer
  • Hormone receptors
  • Human epidermal growth factor receptor 2
  • Interaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. / Neven, P.; Van Calster, B.; Van Den Bempt, I.; Van Huffel, S.; Van Belle, V.; Hendrickx, Wouter R.; Decock, Julie; Wildiers, H.; Paridaens, R.; Amant, F.; Leunen, K.; Berteloot, P.; Timmerman, D.; Van Limbergen, E.; Weltens, C.; Van Den Bogaert, W.; Smeets, A.; Vergote, I.; Christiaens, M. R.; Drijkoningen, M.

In: Breast Cancer Research and Treatment, Vol. 110, No. 1, 01.07.2008, p. 153-159.

Research output: Contribution to journalArticle

Neven, P, Van Calster, B, Van Den Bempt, I, Van Huffel, S, Van Belle, V, Hendrickx, WR, Decock, J, Wildiers, H, Paridaens, R, Amant, F, Leunen, K, Berteloot, P, Timmerman, D, Van Limbergen, E, Weltens, C, Van Den Bogaert, W, Smeets, A, Vergote, I, Christiaens, MR & Drijkoningen, M 2008, 'Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer', Breast Cancer Research and Treatment, vol. 110, no. 1, pp. 153-159. https://doi.org/10.1007/s10549-007-9687-4
Neven, P. ; Van Calster, B. ; Van Den Bempt, I. ; Van Huffel, S. ; Van Belle, V. ; Hendrickx, Wouter R. ; Decock, Julie ; Wildiers, H. ; Paridaens, R. ; Amant, F. ; Leunen, K. ; Berteloot, P. ; Timmerman, D. ; Van Limbergen, E. ; Weltens, C. ; Van Den Bogaert, W. ; Smeets, A. ; Vergote, I. ; Christiaens, M. R. ; Drijkoningen, M. / Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer. In: Breast Cancer Research and Treatment. 2008 ; Vol. 110, No. 1. pp. 153-159.
@article{2cad50562ae84dd5863f465266fc10e6,
title = "Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer",
abstract = "Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely HER-2 + and HER-2+ tumours are less likely ER+. Methods: We studied the age-related immunohistochemical (IHC) expression of ER, progesterone receptor (PR) and HER-2 in 2,227 tumours using age as a continuous variable. Steroid receptors were considered positive for any nuclear staining of invasive cancer cells and for HER-2, either for strong expression by IHC (score 3+) or gene amplification by fluorescence in situ hybridisation (FISH). Based on nonparametric regression, the age-related association between steroid receptors and HER-2 was presented as likelihood curves. Results: The association between ER or PR and HER-2 is age-related. The age-related expression of ER and PR is HER-2 dependent. In HER-2- cases, the odds ratio (OR) for being ER+ was 2.594 (95{\%} CI = 1.874-3.591) up to age 50 and age-independent thereafter; for PR-expression the OR was 2.687 (95{\%} CI = 1.780-4.057) up to age 45 and 0.847 (95{\%} CI = 0.761-0.942) thereafter. In HER-2+ cases, the OR was 0.806 (95{\%} CI = 0.656-0.991) to be ER + and 0.722 (95{\%} CI = 0.589-0.886) to be PR+. The age-related OR for breast cancers to be HER-2+ is steroid receptor dependent. Taking together, ER+PR+HER-2+ breast cancers appear on average 5.4 years earlier than breast cancers of any other ER/PR/HER-2 phenotype (95{\%} CI = 3.3-7.5; P < 0.0001). Conclusion: There is a qualitative interaction between age and expression of steroid and HER-2 receptors. Our findings suggest a strong age-related selective growth advantage for breast tumour cells belonging to the ER+PR+HER-2 + subgroup.",
keywords = "Breast cancer, Hormone receptors, Human epidermal growth factor receptor 2, Interaction",
author = "P. Neven and {Van Calster}, B. and {Van Den Bempt}, I. and {Van Huffel}, S. and {Van Belle}, V. and Hendrickx, {Wouter R.} and Julie Decock and H. Wildiers and R. Paridaens and F. Amant and K. Leunen and P. Berteloot and D. Timmerman and {Van Limbergen}, E. and C. Weltens and {Van Den Bogaert}, W. and A. Smeets and I. Vergote and Christiaens, {M. R.} and M. Drijkoningen",
year = "2008",
month = "7",
day = "1",
doi = "10.1007/s10549-007-9687-4",
language = "English",
volume = "110",
pages = "153--159",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

AU - Neven, P.

AU - Van Calster, B.

AU - Van Den Bempt, I.

AU - Van Huffel, S.

AU - Van Belle, V.

AU - Hendrickx, Wouter R.

AU - Decock, Julie

AU - Wildiers, H.

AU - Paridaens, R.

AU - Amant, F.

AU - Leunen, K.

AU - Berteloot, P.

AU - Timmerman, D.

AU - Van Limbergen, E.

AU - Weltens, C.

AU - Van Den Bogaert, W.

AU - Smeets, A.

AU - Vergote, I.

AU - Christiaens, M. R.

AU - Drijkoningen, M.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely HER-2 + and HER-2+ tumours are less likely ER+. Methods: We studied the age-related immunohistochemical (IHC) expression of ER, progesterone receptor (PR) and HER-2 in 2,227 tumours using age as a continuous variable. Steroid receptors were considered positive for any nuclear staining of invasive cancer cells and for HER-2, either for strong expression by IHC (score 3+) or gene amplification by fluorescence in situ hybridisation (FISH). Based on nonparametric regression, the age-related association between steroid receptors and HER-2 was presented as likelihood curves. Results: The association between ER or PR and HER-2 is age-related. The age-related expression of ER and PR is HER-2 dependent. In HER-2- cases, the odds ratio (OR) for being ER+ was 2.594 (95% CI = 1.874-3.591) up to age 50 and age-independent thereafter; for PR-expression the OR was 2.687 (95% CI = 1.780-4.057) up to age 45 and 0.847 (95% CI = 0.761-0.942) thereafter. In HER-2+ cases, the OR was 0.806 (95% CI = 0.656-0.991) to be ER + and 0.722 (95% CI = 0.589-0.886) to be PR+. The age-related OR for breast cancers to be HER-2+ is steroid receptor dependent. Taking together, ER+PR+HER-2+ breast cancers appear on average 5.4 years earlier than breast cancers of any other ER/PR/HER-2 phenotype (95% CI = 3.3-7.5; P < 0.0001). Conclusion: There is a qualitative interaction between age and expression of steroid and HER-2 receptors. Our findings suggest a strong age-related selective growth advantage for breast tumour cells belonging to the ER+PR+HER-2 + subgroup.

AB - Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely HER-2 + and HER-2+ tumours are less likely ER+. Methods: We studied the age-related immunohistochemical (IHC) expression of ER, progesterone receptor (PR) and HER-2 in 2,227 tumours using age as a continuous variable. Steroid receptors were considered positive for any nuclear staining of invasive cancer cells and for HER-2, either for strong expression by IHC (score 3+) or gene amplification by fluorescence in situ hybridisation (FISH). Based on nonparametric regression, the age-related association between steroid receptors and HER-2 was presented as likelihood curves. Results: The association between ER or PR and HER-2 is age-related. The age-related expression of ER and PR is HER-2 dependent. In HER-2- cases, the odds ratio (OR) for being ER+ was 2.594 (95% CI = 1.874-3.591) up to age 50 and age-independent thereafter; for PR-expression the OR was 2.687 (95% CI = 1.780-4.057) up to age 45 and 0.847 (95% CI = 0.761-0.942) thereafter. In HER-2+ cases, the OR was 0.806 (95% CI = 0.656-0.991) to be ER + and 0.722 (95% CI = 0.589-0.886) to be PR+. The age-related OR for breast cancers to be HER-2+ is steroid receptor dependent. Taking together, ER+PR+HER-2+ breast cancers appear on average 5.4 years earlier than breast cancers of any other ER/PR/HER-2 phenotype (95% CI = 3.3-7.5; P < 0.0001). Conclusion: There is a qualitative interaction between age and expression of steroid and HER-2 receptors. Our findings suggest a strong age-related selective growth advantage for breast tumour cells belonging to the ER+PR+HER-2 + subgroup.

KW - Breast cancer

KW - Hormone receptors

KW - Human epidermal growth factor receptor 2

KW - Interaction

UR - http://www.scopus.com/inward/record.url?scp=44849141664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849141664&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9687-4

DO - 10.1007/s10549-007-9687-4

M3 - Article

C2 - 17687649

AN - SCOPUS:44849141664

VL - 110

SP - 153

EP - 159

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -